MoonLake Immunotherapeutics (MLTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.06B
Last updated: Nov 17, 2026 at 11:06 AM ET
MoonLake Immunotherapeutics (MLTX) Stock Forecast
Analysts expect MoonLake Immunotherapeutics (MLTX) to earn -$3.58 per share in the fiscal year ending Dec 31, 2026. Of 15 analysts, 11 rate the stock Buy or Strong Buy, 2 Hold and 2 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$3.40.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 15 ratings average 2.33, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 73% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 6.7% |
| Buy | 10 | 66.7% |
| Hold | 2 | 13.3% |
| Sell | 2 | 13.3% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 15
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$3.58
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$3.40
- EPS consensus, revenue $19.18M
- Next report
- Feb 22, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$3.58 | -$3.69 to -$3.15 | 8 | N/A | N/A | 13 |
| Dec 31, 2027 | -$3.40 | -$4.11 to -$2.73 | 9 | $19.18M | N/A | 13 |
Quarterly Estimates
The EPS consensus falls from -$0.84 for the quarter ending Dec 31, 2026 to -$0.94 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.84 | -$0.99 to -$0.69 | 15 | N/A | N/A | 14 |
| Mar 31, 2027 | -$0.94 | -$1.18 to -$0.79 | 3 | $74750 | N/A | 8 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 6 upward and 1 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2027 | 5 | 1 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$3.36.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$3.58 | -$3.38 | -$3.38 | -$3.38 | -$3.36 | N/A |
| Fiscal year ending Dec 31, 2027 | -$3.40 | -$3.33 | -$3.33 | -$3.33 | -$3.33 | N/A |
| Quarter ending Mar 31, 2027 | -$0.94 | -$1.03 | -$1.03 | -$1.03 | -$0.87 | N/A |
Frequently Asked Questions About MLTX
What is the MLTX stock forecast?
Consensus analyst estimates put MoonLake Immunotherapeutics's EPS at -$3.58 for the fiscal year ending Dec 31, 2026. The consensus rating from 15 analysts is Buy.
How do analysts rate MLTX stock?
Of 15 analysts covering MoonLake Immunotherapeutics, 1 rates it Strong Buy, 10 Buy, 2 Hold, 2 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from MLTX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.58, with estimates from -$3.69 to -$3.15 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$3.40, with estimates from -$4.11 to -$2.73 from 9 analysts.
What revenue do analysts expect from MoonLake Immunotherapeutics next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $19.18M.
How many analysts cover MLTX?
15 analysts rate MoonLake Immunotherapeutics stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
MLTX pages: Overview, Earnings, Forecast, Financials, Competitors